Tools   Select Another Resource Report Type

https://ganjoho.jp/public/index.html

Portal provides information on Cancer Statistics in Japan. Official website operated by National Cancer Center for cancer information.

Proper citation: Cancer Information Service (RRID:SCR_024445) Copy   

•   Source: SciCrunch Registry

http://www.bwhct.nhs.uk/wmrgl/biobank-cehrb

The Central England Haemato-Oncology Research Biobank stores excess material from oncology samples referred for diagnostic testing and disease monitoring at the West Midlands Regional Genetics Laboratory (WMRGL). The bank is housed within the WMRGL. Types of material stored include viable cells, fixed cell suspensions, DNA, RNA / cDNA, and plasma. The material is made available to all cancer research groups both locally and nationally. Excess sample (mainly from blood and bone marrow) is stored from diagnostic patient material and from samples received throughout their disease course. The WMRGL serves a population of about 5.5 million and is the largest UK NHS genetic Lab. Due to the large patient population CEHRB is able to collate sufficient research material from all classifications of neoplastic haematological disorders including those that are rare.

Proper citation: Central England Haemato-Oncology Research Biobank (RRID:SCR_004637) Copy   

•   Source: SciCrunch Registry

http://ccr.coriell.org/Sections/Collections/Wistar/?SsId=74

Collection of cell lines developed by Wistar scientists that includes a group of hybridomas that produce monoclonal antibodies that are useful in influenza research and vaccine development, melanoma cell lines derived from patients with diseases ranging from mild dysplasia to advanced metastatic cancer and a range of human endothelial cell lines.

Proper citation: Wistar Institute Collection at Coriell (RRID:SCR_004660) Copy   

•   Source: SciCrunch Registry

http://www.ngfn.de/en/start.html

The program of medical genome research is a large-scale biomedical research project which extends the national genome research net (NGFN) and will be funded by the federal ministry of education and research (BMBF) from 2008-2013. Currently the program includes two fields: * Research ** NGFN-Plus: With the aim on combating diseases that are central to health policy, several hundred researchers are systematically investigating the complex molecular interactions of the human body. They are organized in 26 Integrated Genome Research Networks. * Application ** NGFN-Transfer: The rapid transfer of results from medical genome research into medical and industrial application is the aim of the scientists from research institutes and biomedical enterprises that cooperate in eight Innovation Alliances. AREAS OF DISEASE * Cardiovascular disease * Cancer * Neuronal diseases * Infections and Inflammations * Environmental factors

Proper citation: National Genome Research Network (RRID:SCR_006626) Copy   

•   Source: SciCrunch Registry

http://www.lji.org/faculty-research/scientific-cores/functional-genomics-sequencing-core/#overview

Non profit collaborative research organization located in La Jolla, California, UCSD Research Park. Institute researches immunology and immune system diseases to pinpoint specific genes involved, accelerate progress toward development of new treatments and vaccines to prevent and cure type 1 diabetes, cancer and infectious disease. Developer of Immune Epitope Database (IEDB). Provides core facilities with access to equipment, technologies, training and expertise to support innovative research.

Proper citation: La Jolla Institute for Immunology (RRID:SCR_014837) Copy   

•   Source: SciCrunch Registry

http://sharedresources.fredhutch.org/core-facilities/cceh-administration

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on July,27,2022. Core facility that provides scientific and budgetary oversight for all CCEH activities. This includes training programs, high school summer internships, and and pilot and feasibility program for new projects.

Proper citation: Fred Hutchinson Cancer Research Center Co-operative Center for Excellence in Hematology (RRID:SCR_015320) Copy   

•   Source: SciCrunch Registry

https://www.med.upenn.edu/cbica/captk/

Software platform for analysis of radiographic cancer images. Used as quantitative imaging analytics for precision diagnostics and predictive modeling of clinical outcome.

Proper citation: Cancer Imaging Phenomics Toolkit (RRID:SCR_017323) Copy   

•   Source: SciCrunch Registry

http://www.cancergenomics.org/

Consortium promoting communication and collaboration among cancer cytogenomics laboratories, who are interested in applying microarray technologies to cancer diagnosis and cancer research. Their oals are to (1) establish platform-neutral and cancer specific microarray designs for diagnostic purposes, (2) share cancer microarray data between participating institutions for education purposes, (3) create a public cancer array database, and (4) carry out multicenter cancer genome translational research. Collaboration amongst the different laboratories and researchers will not only provide validation for the microarray design(s) but ultimately provide more comprehensive molecular information and more accurate interpretation to better serve cancer patients and further cancer research. The CGC was officially incorporated in June 2010 as a not-for-profit organization.

Proper citation: Cancer Genomics Consortium (RRID:SCR_002384) Copy   

•   Source: SciCrunch Registry

https://cghub.ucsc.edu/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on March 17, 2022. A secure repository for storing, cataloging, and accessing cancer genome sequences, alignments, and mutation information from the Cancer Genome Atlas (TCGA) consortium and related projects. CGHub gives scientific researchers the statistical power of large cancer genome datasets to attack the molecular complexity of cancer.

Proper citation: Cancer Genomics Hub (RRID:SCR_002657) Copy   

•   Source: SciCrunch Registry

http://www.dtp.nci.nih.gov

Portal for preclinical information and research materials, including web-accessible data and tools, NCI-60 Tumor Cell Line Screen, compounds in vials and plates, tumor cells, animals, and bulk drugs for investigational new drug (IND)-directed studies. DTP has been involved in the discovery or development of more than 70 percent of the anticancer therapeutics on the market today, and will continue helping the academic and private sectors to overcome various therapeutic development barriers, particularly through supporting high-risk projects and therapeutic development for rare cancers. Initially DTP made its drug discovery and development services and the results from the human tumor cell line assay publicly accessible to researchers worldwide. At first, the site offered in vitro human cell line data for a few thousand compounds and in vitro anti-HIV screening data for roughly 42,000 compounds. Today, visitors can find: * Downloadable in vitro human tumor cell line data for some 43,500 compounds and 15,000 natural product extracts * Results for 60,000 compounds evaluated in the yeast assay * In vivo animal model results for 30,000 compounds * 2-D and 3-D chemical structures for more than 200,000 compounds * Molecular target data, including characterizations for at least 1,200 targets, plus data from multiple cDNA microarray projects In addition to browsing DTP's databases and downloading data, researchers can request individual samples or sets of compounds on 96-well plates for research, or they can submit their own compounds for consideration for screening via DTP's online submission form. Once a compound is submitted for screening, researchers can follow its progress and retrieve data using a secure web interface. The NCI has collected information on almost half a million chemical structures in the past 50 years. DTP has made this information accessible and useful for investigators through its 3-D database, a collection of three-dimensional structures for more than 200,000 drugs. Investigators use the 3-D database to screen compounds for anticancer therapeutic activity. Also available on DTP's website are 127,000 connection tables for anticancer agents. A connection table is a convenient way of depicting molecular structures without relying on drawn chemical structures. As unique lists of atoms and their connections, the connection tables can be indexed and stored in computer databases where they can be used for patent searches, toxicology studies, and precursor searching, for example., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Developmental Therapeutics Program (RRID:SCR_003057) Copy   

•   Source: SciCrunch Registry

http://bioinformatics.istge.it/cldb/indexes.html

Hypertext on cell culture availability extracted from the Cell Line Data Base of the Interlab Project. HyperCLDB includes links to records of OMIM, the Online Mendelian Inheritance in Man Catalogue, and now also links to the PubMed, database of bibliographic biomedical references, which are drawn primarily from MEDLINE and PREMEDLINE.

Proper citation: Hyper Cell Line Database (RRID:SCR_007730) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29332&a=31537&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented on April 4, 2014. Tissue Biobank collects samples from different types of cancers patients prospectively. Blood samples are being sent to KI Biobank for DNA extraction and storage. Number of sample donors: 611 (June 2010)

Proper citation: KI Biobank - Tissue Biobank (RRID:SCR_006043) Copy   

•   Source: SciCrunch Registry

http://biobankireland.com/

Biobank Ireland Trust promotes the development of an Irish Hospital Biobank Network to coordinate collection of small samples of cancer and normal tissue and coded patient data from those having a cancer operation. This will facilitate international molecular research collaborations, which may help identify the best treatment for each individual patient - personalized medicine. Biobank Ireland is promoting the development of a Hospital Biobank Network throughout the island of Ireland as a bridge between cancer research and care. This new infrastructure will facilitate large national and international translational research collaborations that will raise Ireland''s research profile and benefit those with cancer. Researchers will have online access to samples and to restricted patient data from participating hospitals and an equitable withdrawal process for scientifically and ethically approved projects. Important research results will be explained to the public. Other Objectives: * To facilitate (inter)national translational research collaborations that may lead to new tests and better, less toxic treatments for those with cancer * To enable molecular research on cancer tissue from clinical trials patients identify the best treatment for each individual patient ������??personalized medicine������?? * Researchers will have online access to samples and restricted patient data from participating hospitals, and a fair release process for scientifically and ethically approved projects * Biobank Ireland recognizes the need to have harmonization in biobanking around the world * Important research results will be explained to the public * Biobank Ireland will seek to have the hospital-based Biobank Network funded by government as standard of care

Proper citation: Biobank Ireland Trust (RRID:SCR_006430) Copy   

•   Source: SciCrunch Registry

http://www.kccmr.org/

This colony provides a national resource of rhesus monkeys and their tissues to carry out research benefiting the scientific community. The RMBRR maintains a colony of monkeys that have been derived to be specific pathogen free for members of both the herpes and retrovirus families. Over its history, the RMBRR has developed specialized management techniques, housing facilities and highly trained staff to avail these purposefully bred laboratory models, which are 93% genetically identical to humans, to researchers worldwide. Historically, this animal model has been instrumental in research involving blood classification, polio vaccine development, and drug safety and efficacy while currently they are the preferred model for studying the mechanisms of immunodeficiency diseases. Their susceptibility to Simian Immunodeficiency Virus and their homology to the human major histocompatibility complex (MHC) Class I, II and TCR genes make them valuable in HIV research. They are currently the models of choice for HIV/AIDS vaccine development and study. Other areas of research include atherosclerosis, myocarditis, alcoholism, diabetes, cancer and aging. The overall objectives of this resource are to improve the resources available at the RMBRR and to conduct resource-relevant research that improves both the health of the rhesus colony and its usefulness for studies of human disease. The Resource and Management Core is responsible for providing animal resources, tissues/biological fluids, cell lines, expert advice and research support to NIH extramural and intramural programs, other federal agencies and to private sponsors. The Resource-Related Research Core conducts research to improve the health of the animals maintained with special emphasis on studies that will enhance the usefulness of the rhesus as a model for studies of human disease.

Proper citation: Rhesus Monkey Breeding and Research (RRID:SCR_008357) Copy   

•   Source: SciCrunch Registry

http://www.cnio.es/ES/grupos/plantillas/presentacion.asp?grupo=50004308

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 29, 2016. The need to use human neoplastic tissue under ideal conditions is currently of particular importance due to the development molecular pathology techniques that allow large-scale studies of genetic expression that are also of clinical significance. The Tumour Bank Network (TBN), instigated and coordinated by the Molecular Pathology Programme (MMP) aims to respond to this need by the promoting of Tumour Banks in Spanish hospitals. This will be achieved through the application of homogeneous procedures for the collection, processing and storage of neoplastic and normal tissue samples in such a way as to make molecular studies possible, avoiding that avoid the intrinsic bias of multi-centre studies possible. These Hospital Tumour Banks are based within the Pathology Departments of the collaborating Hospitals, that are interconnected through a computer-based network. In this way, each Centre''s tissue remains in the Hospital itself, thereby playing a key role in the development of the welfare, teaching and research activities within the Hospital. At the same time, it represents a tool to encourage of multi-hospital cancer research and of cooperation between basic and clinical researchers, constituting important collaboration between biomedical disciplines. The design does not correspond to a Central Tumour Bank, but that of a cooperative and coordinated Network of Hospital Banks, based on simple, homogeneous and optimal tissue treatment protocols. This Network is promoted by the Centro Nacional de Investigaciones Oncologicas (CNIO), which thereby undertakes the work of coordinating the network, using and maintaining the database, adhering to quality control. The aim of the CNIO's TBN is to acquire neoplastic and control non-neoplastic material of all types of malignant neoplasias, in the form of tissue fixed in formalin and paraffin embedded, of samples that are unfixed or frozen according to conventional methods as set out in Annexe 1 and even, exceptionally as fresh tissue. When other types of samples are required to carry out a specific project, the central office of the TBN will draw up a protocol with the group leading the project for the collection and maintenance of the tissue and clinicopathological data required for the proposed research. These protocols will be disseminated among the Associated Hospitals in order to gather the previously agreed number cases. Basic data surrounding the processing and preservation conditions for each case will be sent to the central office of the Bank, which under no circumstances will reveal the identity of the patient. Any Spanish cancer research team will be able to request tissue from the Tissue Bank Network. Absolute priority will be afforded to projects whose principal researcher belongs to one of the Associated Centres of the TNB, to other institutions with special agreements concerning the exchange of samples, and to the CNIO's researchers.

Proper citation: Spanish National Tumour Bank Network (RRID:SCR_008707) Copy   

•   Source: SciCrunch Registry

http://www.cravat.us/

A web-based application designed with an easy-to-use interface to facilitate the high-throughput assessment and prioritization of genes and missense alterations important for cancer tumorigenesis.

Proper citation: CRAVAT (RRID:SCR_012776) Copy   

•   Source: SciCrunch Registry

https://abctb.org.au/abctbNew2/default.aspx

A tissue bank which houses and supplies cancerous tissue for use by the research community. Along with tissue, the bank collects clinical history, lifestyle factors, breast pathology, treatment information, and follow up information.

Proper citation: Australia Breast Cancer Tissue Bank (RRID:SCR_000926) Copy   

•   Source: SciCrunch Registry

http://dtp.nci.nih.gov/branches/btb/services.html

National Cancer Institute Biorepositories provides information on the tumor repository, animal production program, and access to other NIH Repositories. A catalog of in vitro cell lines, transplantable animal and human tumors and microarrays, including ordering information, is available. In the Animal Production Program, rodents are supplied to Federal Institutions and to grantees/contractors with a current OLAW Assurance on file. Requests from international entities seeking rodent strains solely available from the NCI Animal Production Program must have an OLAW Assurance or current AAALACi accreditation and will be evaluated on a case-by-case basis. In general, the rodents are supplied to the following: * Researchers at NCI-Frederick * NIH on-campus laboratories * NIH/NCI funded research contracts * NIH/NCI funded grantees * Other government agencies To meet the above needs, animal production contracts plus quality control contracts are used. The animal production contracts are used to propagate the NIH sublines of the strains. Many of the strains produced are not available commercially and the NCI program is the sole source of several lines.

Proper citation: National Cancer Institute Biorepositories (RRID:SCR_004789) Copy   

•   Source: SciCrunch Registry

http://www.medunigraz.at/en/biobank

Biobank Graz is a non-profit central Medical University of Graz (MUG) service facility that provides the logistics and infrastructure to optimally support MUG research teams in the collection, processing and storage of biological samples and their associated data. In the course of this, special attention is given to sample and data quality and to the protection of the individual rights of patients. Samples from selected patients at the Graz LKH-University Clinical Centre, who have signed an informed consent declaration, are deposited in Biobank Graz. This means that excess tissue and blood samples are collected and placed in storage. The samples are harvested in the course of routine interventions undertaken by the different departments and institutes of the Graz LKH-University Clinical Centre and approved for use in research projects only after the completion of all necessary laboratory and histopathological analyses. No additional material is removed: in other words, there are no associated drawbacks whatsoever for the patients involved. Biobank Graz operates a quality management system according to ISO 9001:2008 and offers the following services for the processing and storage of biological samples and the handling of data: * Consistently high sample quality through the processing of samples using standardized methods in accordance with written working instructions (SOPs) * Efficient use of resources through the building of shared infrastructure and the development of optimized processes * A high degree of reliability provided by the storage of samples in 24/7 - monitored storage systems. * Processing and storage of all data in accordance with data protection legislation. Biobank Graz comprises both population-based and disease-focused collections of biological materials. It currently contains approx. 3.8 mio samples from approx. 1.2 mio patients representing a nonselected patient group characteristic of central Europe. Because the Institute of Pathology was, until 2003, the exclusive pathology service provider for major parts of the province of Styria, including its capital Graz (population approx. 1.2 mio people), samples from all human diseases, treated by surgery or diagnosed by biopsy, are included in the collection at their natural frequency of occurrence and thus represent cancers and non-cancerous diseases from all organs, and from all age groups. The scientific value of the existing tissue collection is, thus, not only determined by its size and technical homogeneity (all samples have been processed in a single institute under constant conditions for more than 20 years), but also by its population-based character. These features provide ideal opportunities for epidemiological studies and allow the validation of biomarkers for the identification of specific diseases and determination of their response to treatment. Prospectively collected tissues, blood samples and clinical data comprise, on the one hand, randomly selected samples from all diseases and patient groups to provide sufficient numbers of samples for the evaluation of the disease-specificity of any gene or biomarker. On the other hand, Biobank Graz adopts a disease-focused approach for selected diseases (such as breast, colon and liver cancers as well as some metabolic diseases) through the collection of a range of different human biological samples of highest quality and detailed clinical follow-up data. Graz Medical University established the Biobank to provide improved and sustainable access to biological samples and related (clinical) data both for its own academic research and for external research projects of academic and industrial partners. It is a major interest of the university to initiate co-operative research projects. Biological samples and data are available to external institutions performing high-quality research projects which comply with the Biobank''s ethical and legal framework according to the access rules (Contact: COO Karine Sargsyan, MD, PhD).

Proper citation: Biobank Graz (RRID:SCR_004245) Copy   

•   Source: SciCrunch Registry

http://www.roswellpark.edu/shared-resources/data-bank-and-biorepository

Collects and provides de-identified biospecimens and associated epidemiological and clinical data to meet the scientific needs of investigators. Newly diagnosed patients are asked to contribute data and specimens to the DBBR prior to treatment. Other patients with who have benign disease or advanced disease and have undergone treatment are also enrolled based on anticipated use of data and samples for research. Additionally, non-patients (family members and friends of patients and community members) with no personal history of cancer are asked to participate in the biorepository as controls. Specimens and data are procured with protected health information (PHI) and de-identified prior to distribution to investigators with hypothesis driven IRB reviewed studies. An extensive data collection and management system is in place to track informed consent, questionnaire collection and follow up, epidemiological questionnaire data, clinical data, biospecimens and their derivatives. Research Services * Availability of a bank of prospectively collected blood specimens (serum, plasma, buffy coat, red blood cells and DNA) from cancer patients, high risk individuals and healthy controls for research. * Collection, linking and distribution of epidemiologic and clinical data with biospecimens. * Study-specific biospecimen and data procurement to meet the needs of individual studies, including: ** Participant identification, eligibility screening and informed consent ** Serial biospecimen procurement prior to and throughout treatment ** Study specific collection of biospecimens other than blood (buccal cells, sputum, and urine) ** Procurement and distribution of fresh biospecimens ** Collection of extended clinical and risk factor data

Proper citation: Roswell Park Data Bank and BioRepository (RRID:SCR_003607) Copy   

•   Source: SciCrunch Registry